These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22586072)

  • 1. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.
    Santen RJ; Yue W; Heitjan DF
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1038-48. PubMed ID: 22586072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult breast tumor reservoir: biological properties and clinical significance.
    Santen RJ; Yue W; Heitjan DF
    Horm Cancer; 2013 Aug; 4(4):195-207. PubMed ID: 23632998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of menopausal hormonal therapy on occult breast tumors.
    Santen RJ; Song Y; Yue W; Wang JP; Heitjan DF
    J Steroid Biochem Mol Biol; 2013 Sep; 137():150-6. PubMed ID: 23748149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women's Health Initiative study.
    Santen RJ; Yue W
    Climacteric; 2019 Feb; 22(1):3-12. PubMed ID: 30380950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet Oncol; 2012 Nov; 13(11):1141-51. PubMed ID: 23084519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
    Radmacher MD; Simon R
    J Natl Cancer Inst; 2000 Jan; 92(1):48-53. PubMed ID: 10620633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors and breast cancer prevention.
    Litton JK; Arun BK; Brown PH; Hortobagyi GN
    Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
    Simon JA; Nahum GG; Stanislaw H; Gaines T
    Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status.
    Gaudet MM; Britton JA; Kabat GC; Steck-Scott S; Eng SM; Teitelbaum SL; Terry MB; Neugut AI; Gammon MD
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1485-94. PubMed ID: 15342450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hormones in cancer prevention.
    Vogel VG
    Am Soc Clin Oncol Educ Book; 2014; ():34-40. PubMed ID: 24857058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen and breast density in women at increased risk of breast cancer.
    Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
    J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
    Glaser RL; Dimitrakakis C
    Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.